Advances in the Diagnosis and Treatment of Amyloidosis in 2026 is a CME-accredited educational conference that provides an update on the latest developments in systemic and cardiac amyloidosis, including AL (light-chain) and ATTR (transthyretin) amyloidosis. The program covers advances in early diagnosis, multimodality imaging, biomarkers, genetic testing, pathology, and emerging disease-modifying therapies. Participants will learn practical approaches to recognizing amyloidosis earlier, selecting appropriate diagnostic pathways, and implementing current evidence-based treatments to improve patient outcomes. The conference features expert faculty, case-based discussions, and multidisciplinary perspectives from cardiology, hematology, neurology, nephrology, and pathology.